A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
A phase 1/2 trial of Giredestrant, Abemaciclib, Ipatasertib, Inavolisib, Ribociclib and Everolimus in HR-positive / HER2-negative breast cancer, run by Hoffmann-La Roche, now recruiting.
Overview
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer is a phase 1/2 interventional study registered as NCT04802759 by Hoffmann-La Roche, with 316 participants planned, started 2021-06-22 and due to reach its primary completion in 2029-05-30. Interventions recorded: Giredestrant, Abemaciclib, Ipatasertib, Inavolisib, Ribociclib and Everolimus.
Similar pages
not linked directly; found by shared links- TrialA Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
Shares Giredestrant, Inavolisib, Ribociclib, Flatiron Health (Roche) and the tag pipeline.
- TrialA Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Shares Giredestrant, Ribociclib, Flatiron Health (Roche), Abemaciclib and the tag pipeline.
- TrialA Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Shares Giredestrant, Flatiron Health (Roche), Abemaciclib, HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialA Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
Shares Inavolisib, Ribociclib, Flatiron Health (Roche) and the tag pipeline.
- TrialA Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Shares Inavolisib, Flatiron Health (Roche), HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialA Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)
Shares Giredestrant, Flatiron Health (Roche), HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialA Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
Shares Inavolisib, Flatiron Health (Roche), HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialA Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
Shares Everolimus, Ribociclib, Abemaciclib and the tag pipeline.